Researchers discover ‘Achilles’ heel’ for lymphoid leukemia
February 11, 2013 by admin · Leave a Comment
An international research team coordinated at the IRCM in Montréal found a possible alternative treatment for lymphoid leukemia. Led by Dr. Tarik Möröy, the IRCM’s President and Scientific Director, the team discovered a molecule that represents the disease’s “Achilles’ heel” and could be targeted to develop a new approach that would reduce the adverse effects of current treatments such as chemotherapy and radiation therapy. The study’s results are being published today in the prestigious scientific journal Cancer Cell.
Experimental drug combination selectively destroys lymphoma cells
February 6, 2013 by admin · Leave a Comment
Laboratory experiments conducted by scientists at Virginia Commonwealth University Massey Cancer Center suggest that a novel combination of the drugs ibrutinib and bortezomib could potentially be an effective new therapy for several forms of blood cancer, including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).
New way to kill lymphoma without chemotherapy
January 21, 2013 by admin · Leave a Comment
How do you annihilate lymphoma without using any drugs?
Starve it to death by depriving it of what appears to be a favorite food: HDL cholesterol.
Northwestern Medicine® researchers discovered this with a new nanoparticle that acts like a secret double agent. It appears to the cancerous lymphoma cell like a preferred meal — natural HDL. But when the particle engages the cell, it actually plugs it up and blocks cholesterol from entering. Deprived of an essential nutrient, the cell eventually dies.
Scientists harness immune system to prevent lymphoma relapse
October 18, 2012 by admin · Leave a Comment
UK scientists hope that lymphoma patients could benefit from a new drug that triggers the cancer-fighting properties of the body’s own immune system, after highly promising early laboratory results.
Moffitt Cancer Center researchers find potential key to new treatment for mantle cell lymphoma
July 18, 2012 by admin · Leave a Comment
Researchers at Moffitt Cancer Center and colleagues have demonstrated that the inhibition of signal transducer and activator of transcription 3 (STAT3) in mouse models of mantle cell lymphoma (MCL), an aggressive and incurable subtype of B-cell non-Hodgkin lymphoma that becomes resistant to treatment, can harness the immune system to eradicate residual malignant cells responsible for disease relapse.
Stopping and starting cancer cell cycle weakens and defeats multiple myeloma
June 21, 2012 by admin · Leave a Comment
Weill Cornell Medical College researchers have devised an innovative boxer-like strategy, based on the serial use of two anti-cancer drugs, to deliver a one-two punch to first weaken the defenses of multiple myeloma and then deliver the final knock-out punch to win the fight.
New drug strategy attacks resistant leukemia and lymphoma
May 28, 2012 by admin · Leave a Comment
Scientists at the Dana-Farber/Children’s Hospital Cancer Center have developed an anti-cancer peptide that overcomes the stubborn resistance to chemotherapy and radiation often encountered in certain blood cancers when the disease recurs following initial treatment.
Researchers make promising discovery in pursuit of effective lymphoma treatments
May 15, 2012 by admin · Leave a Comment
Researchers at NYU School of Medicine have identified a target for slowing the progression of multiple myeloma by using currently available drugs.
Published recently in Nature Cell Biology, the study reveals a pathway that, if deactivated, may help slow the development of the disease.
New compound targets key mechanism behind lymphoma
April 2, 2012 by admin · Leave a Comment
Scientists at Fox Chase Cancer Center in Philadelphia have come one step closer to developing the first treatment to target a key pathway in lymphoma. The new findings will be announced at the AACR Annual Meeting 2012 on Tuesday, April 3.
Researchers develop first ‘theranostic’ treatment for acute lymphoblastic leukemia (ALL)
March 6, 2012 by admin · Leave a Comment
A team of researchers at Case Western Reserve University School of Medicine has developed the first “theranostic” agent for the treatment of acute lymphoblastic leukemia (ALL). ALL is the most common type of childhood cancer diagnosed in approximately 5,000 new cases each year in the United States. The findings provide insight into pediatric oncology that specifically focuses on the development of “theranostic” agents– a treatment platform that combines a selective diagnostic test with targeted therapy based on the test results.
